Latest Tax Incentives News

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

CloudHolter Pty Ltd reported a substantial $39.7 million net loss for FY2025 amid ongoing cash outflows but continues to raise capital through convertible notes as it targets an IPO by year-end.

Metals Australia Ltd reports key milestones in its Lac Carheil Graphite Project, achieving battery-grade spherical graphite purity and selecting Sept-Îles as the preferred site for its Battery Anode Material plant.

Euro Manganese Inc. reports significant progress on its Chvaletice Project and Bécancour Plant, positioning itself as a key Western supplier of high-purity manganese critical for EV batteries. The company highlights strong feasibility results, strategic financing partnerships, and multiple offtake agreements amid an expected global supply deficit.

ALCORE, ABx Group’s subsidiary, has secured government approval for overseas R&D activities and is pursuing a $5 million grant to accelerate its clean fluorine chemical technology commercialisation.

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.

333D Limited has responded to ASX queries, clarifying that its Bitcoin Treasury Management Policy approval is not price sensitive, while disclosing a $370,500 Bitcoin acquisition funded partly by R&D tax incentives.

4DMedical has bolstered its financial footing with a $6 million R&D tax incentive and a $10 million strategic investment, while its XV LVAS® technology gains clinical validation for predicting serious COPD treatment complications.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

ClearVue Technologies reported a striking 553% revenue increase to nearly $250,000 in FY2025, alongside a 7% reduction in net loss, driven by strategic partnerships and global project wins.